A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002
This is a Phase 1 study to investigate the safety and tolerability of AK002 in patients with indolent systemic mastocytosis (ISM).
Indolent Systemic Mastocytosis
DRUG: AK002
To evaluate the safety and tolerability by evaluating Clinical laboratory parameters and adverse events assessed using the CTCAE version 4, From study start to Day 85 or early term visit
Evaluate PK of AK002 in patients with ISM, Through out the study from baseline to Day 85 or early term visit|Evaluate the change from baseline in absolute peripheral counts of eosinophils and basophils., Through out the study from screening to Day 85 or early term visit|Evaluate the change from baseline in serum tryptase and eosinophil grande protein levels., Through out the study from screening to Day 29 or early term visit|Measure changes form baseline in the 24-hour urine histamine metabolites., Starting pre dose on day -1 to days 1, 3 and 4|Mastocytosis Quality of Life Questionnaire, Through out the study from screening to Day 85 or early term visit
This is a Phase 1 study to investigate the safety and tolerability of AK002 in patients with indolent systemic mastocytosis (ISM).